Investment
Features
FeesSafety
Academy
More
Pluang+

XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

XRP's circulating market value fell by $61.14 billion, or 42.64%, from $143.38 billion on Oct. 19, 2025, to $82.24 billion a year later, driven by a price drop from $2.39 to $1.30 despite a slight increase in circulating supply. Meanwhile, Evernorth Holdings completed its business combination to form a publicly traded XRP treasury company, raising approximately $300 million in cash and holding about 473 million XRP. The company, trading under XRPN on Nasdaq since Oct. 12, plans to deploy capital across the XRP ecosystem, with XRP's price expected to significantly impact its results.

XRP's market value decline over the past year provides context for cryptocurrency trends. For readers following the crypto market, here is Pluang's market snapshot as of Oct 20, 2026 08:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 16 rose and 33 fell today. Notable movers include BAL at Rp16.297 with an 11.14% increase, BAT at Rp3.444 up 9.20% with a nearly balanced buy/sell order activity, and EOS at Rp12.649 rising 8.13%.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly reported a 20% year-over-year revenue increase to $495 million, supported by 10.2 million active customers and a 197% rise in Free Cash Flow. The company is expanding its product offerings with the Remitly Card and Pay Later services, which, ...

Analyst Insights
Bullish
4 hours ago
NYCB shareholders can pursue claims after judge denies motion to dismiss over alleged governance issues.

NYCB shareholders can pursue claims after judge denies motion to dismiss over alleged governance issues.

New York Community Bank Bancorp (NYCB) faces shareholder claims after a federal judge denied a motion to dismiss allegations that the bank misled investors about governance and loan asset quality. The issues include non-compliance with enhanced prude...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App